A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers

Trial Profile

A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Oct 2015

At a glance

  • Drugs Pioglitazone (Primary) ; Linagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 26 Oct 2015 Planned initiation date changed from 1 Apr 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
    • 26 Oct 2015 Planned number of patients changed from 400 to 160 as reported by ClinicalTrials.gov record.
    • 05 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top